Abbonarsi

Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial - 10/12/14

Doi : 10.1016/j.ahj.2014.10.013 
Masaya Koshizaka, MD, PhD a, Renato D. Lopes, MD, PhD a, Eric M. Reyes, PhD b, C. Michael Gibson, MD c, Phillip J. Schulte, PhD a, Gail E. Hafley, MS a, Adrian F. Hernandez, MD, MHS a, Jennifer B. Green, MD a, Nicholas T. Kouchoukos, MD d, Robert M. Califf, MD e, T. Bruce Ferguson, MD f, Eric D. Peterson, MD, MPH a, John H. Alexander, MD, MHS a,
a Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 
b Rose-Hulman Institute of Technology, Terre Haute, IN 
c PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 
d Missouri Baptist Medical Center, St Louis, MO 
e Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC 
f East Carolina University, Greenville, NC 

Reprint request: John H. Alexander, MD, MHS, Duke Clinical Research Institute, Duke Medicine, Box 3850, Durham, NC 27710.

Riassunto

Background

There is limited information about the association between diabetes, its treatment, and long-term angiographic and clinical outcomes in patients undergoing coronary artery bypass graft surgery (CABG). We evaluated the association of diabetes and its treatment with 1-year angiographic graft failure and 5-year clinical outcomes in patients undergoing CABG.

Methods

Using data from 3,014 patients in PREVENT IV, we analyzed angiographic and clinical outcomes in patients with and without diabetes and among those who did and did not receive insulin before CABG. Logistic regression and Cox proportional hazards models were used to adjust for differences in baseline variables.

Results

Overall, 1,139 (37.8%) patients had diabetes. Of these, 305 (26.8%) received insulin. One-year rates of vein graft failure were similar in patients with and without diabetes but, among diabetics, tended to be higher in patients who received insulin compared with those who did not. At 5 years, rates of death, myocardial infarction, or revascularization were higher among patients with compared with those without diabetes (adjusted hazard ratio 1.57; 95% CI 1.26-1.96; P < .001) and, among diabetics, higher among those who received insulin (adjusted hazard ratio 1.15; 95% CI 1.02-1.30; P = .02).

Conclusions

Patients with diabetes had similar rates of vein graft failure but worse clinical outcomes than patients without diabetes. Patients who received insulin had significantly worse clinical outcomes than patients who did not receive insulin. Further studies to better understand the mechanism behind these findings and to improve the outcomes of patients with insulin-requiring diabetes undergoing CABG surgery are warranted.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 John L Petersen II, MD, MHS, served as guest editor for this article.


© 2014  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 169 - N° 1

P. 175-184 - Gennaio 2015 Ritorno al numero
Articolo precedente Articolo precedente
  • Antistreptokinase antibodies and outcome of fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis
  • Sandeep Singh, Shrenik Doshi, Salman Salahuddin, Mohamad Tarik, Parag Barwad, Lakshmy Ramakrishnan, Sivasubramanian Ramakrishnan, Ganesan Karthikeyan, Balram Bhargava, Vinay K. Bahl
| Articolo seguente Articolo seguente
  • Removal notice to “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial” [Am Heart J. 169/1 (2014) 185]

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.